The DOI matches its Crossref record.
Neuroprotective efficacy of ebselen, an anti‐oxidant with anti‐inflammatory actions, in a rodent model of permanent middle cerebral artery occlusion
Open accessAbstract
The aim of this study was to investigate whether delayed treatment with the anti‐oxidant and anti‐inflammatory agent ebselen reduces the volume of infarction in a rodent model of permanent focal cerebral ischaemia. Ebselen (10 or 30 mg kg−1) or vehicle was administered by gavage 30 min and 12 h after the induction of cerebral ischaemia by permanent occlusion of the left middle cerebral artery (MCA). Animals were killed 24 h following MCA occlusion, and the volumes of ischaemic damage in the ebselen and control groups were evaluated by quantitative histopathology. Ebselen was quickly absorbed following oral (gavage) administration and reached peak levels in the plasma by 1 h post‐administration (plasma selenium level of 0.68±0.04 and 0.84±0.1 μg ml−1 for 10 and 30 mg kg−1, respectively, compared to control level of 0.51±0.02 μg kg−1). Treatment with the lower dose of ebselen (10 mg kg−1) significantly (P<0.01) reduced the volume of infarction in the cerebral hemisphere and cerebral cortex (by 31.8% and 36.7%, respectively compared with the placebo group). The neuroprotective efficacy of the higher dose ebselen (30 mg kg−1) was less than that of the lower dose ebselen (10 mg kg−1). The volume of ischaemic damage in the cerebral hemisphere was reduced by 23.7% (P<0.02), and cerebral cortex by 27.5% (P<0.01). Both doses of ebselen (10, 30 mg kg−1) had no therapeutic efficacy on the caudate nucleus, where ischaemia was most severe, in this model. Free radical‐mediated injury is normally associated with reperfusion of ischaemic tissue. The present results suggest that oxidative injury is also a significant contributor to brain damage in models of maintained (permanent) ischaemia and that ebselen is effective in attenuating this free radical‐induced damage. British Journal of Pharmacology (1997) 122, 1251–1256; doi:10.1038/sj.bjp.0701426
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Organoselenium and Organotellurium Compounds: Toxicology and Pharmacology
Nogueira, C. W., Zeni, G., & Rocha, J. B. T. (2004) · Chemical Reviews · doi:10.1021/cr0406559 · Cited by 1,926
Glutamate receptors, neurotoxicity and neurodegeneration
Lau, A., & Tymianski, M. (2010) · Pflügers Archiv - European Journal of Physiology · doi:10.1007/s00424-010-0809-1 · Cited by 1,185
Neuroprotection for ischemic stroke: Past, present and future
Ginsberg, M. D. (2008) · Neuropharmacology · doi:10.1016/j.neuropharm.2007.12.007 · Cited by 779
Ebselen in Acute Ischemic Stroke: A Placebo-Controlled, Double-blind Clinical Trial
Yamaguchi, T., Sano, K., Takakura, K., Saito, I., Shinohara, Y., Asano, T., & Yasuhara, H. (1998) · Stroke · doi:10.1161/01.str.29.1.12 · Cited by 610
Antioxidant Therapy in Acute Central Nervous System Injury: Current State
Gilgun-Sherki, Y., Rosenbaum, Z., Melamed, E., & Offen, D. (2002) · Pharmacological Reviews · doi:10.1124/pr.54.2.271 · Cited by 568
Toxicology and pharmacology of selenium: emphasis on synthetic organoselenium compounds
Nogueira, C. W., & Rocha, J. B. T. (2011) · Archives of Toxicology · doi:10.1007/s00204-011-0720-3 · Cited by 477
Antioxidant strategies in the treatment of stroke
Margaill, I., Plotkine, M., & Lerouet, D. (2005) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2005.05.003 · Cited by 405
Ebselen, a promising antioxidant drug: mechanisms of action and targets of biological pathways
Azad, G. K., & Tomar, R. S. (2014) · Molecular Biology Reports · doi:10.1007/s11033-014-3417-x · Cited by 343
Ebselen: prospective therapy for cerebral ischaemia
Parnham, M., & Sies, H. (2000) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.9.3.607 · Cited by 283
Oxidative Stress and the Use of Antioxidants in Stroke
Shirley, R., Ord, E., & Work, L. (2014) · Antioxidants · doi:10.3390/antiox3030472 · Cited by 282
Zhao, R., Masayasu, H., & Holmgren, A. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.122061399 · Cited by 254
Self-citationThe role of kupffer cell oxidant production in early ethanol-induced liver disease,
Wheeler, M. (2001) · Free Radical Biology and Medicine · doi:10.1016/s0891-5849(01)00748-1 · Cited by 253
An Overview of Acute Stroke Therapy: Past, Present, and Future
Fisher, M., & Schaebitz, W. (2000) · Archives of Internal Medicine · doi:10.1001/archinte.160.21.3196 · Cited by 112
Hassan, W., Barroso Silva, C., Mohammadzai, I. U., Teixeira da Rocha, J., & Landeira-Fernandez, J. (2014) · Current Neuropharmacology · doi:10.2174/1570159x11666131120232135 · Cited by 100
Chen, Z., Mao, X., Liu, A., Gao, X., Chen, X., Ye, M., Ye, J., Liu, P., Xu, S., Liu, J., et al. (2015) · Neurochemical Research · doi:10.1007/s11064-014-1483-z · Cited by 51
Metadata
- Authors
- Takasago, T., Peters, E. E., Graham, D. I., Masayasu, H., & Macrae, I. M.
- Venue
- British Journal of Pharmacology
- Publisher
- Wiley
- Published
- 1997-11
- Volume
- 122
- Issue
- 6
- Pages
- 1251-1256
- ISSN
- 0007-1188 (ISSN-L)
- 1476-5381
- OpenAlex
- W2020201638
- Cited by
- 161
- References
- 0
- FWCI
- 4.57
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.